Published in Pancreas on August 01, 2010
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer (2013) 1.62
Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery (2015) 1.47
Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist (2012) 1.17
Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol (2013) 1.15
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology (2016) 1.09
Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) (2013) 1.00
A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer (2013) 0.97
A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol (2012) 0.94
Surgical management of pancreatic neuroendocrine tumors. Surg Today (2011) 0.93
Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol (2012) 0.93
Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol (2012) 0.92
Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization. Cancer Res (2013) 0.90
Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. Eur Radiol (2014) 0.90
Differing Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme. Medicine (Baltimore) (2015) 0.89
Neuroendocrine liver metastases: contributions of endoscopy and surgery to primary tumor search. World J Gastroenterol (2012) 0.87
Proposal for a standardized pathology report of gastroenteropancreatic neuroendocrine tumors: prognostic significance of pathological parameters. Korean J Pathol (2013) 0.87
Giant malignant insulinoma. Ann Surg Treat Res (2015) 0.86
Therapy for metastatic pancreatic neuroendocrine tumors. Ann Transl Med (2014) 0.86
Laparoscopic pancreatic surgery for benign and malignant disease. Nat Rev Gastroenterol Hepatol (2016) 0.86
Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. World J Gastroenterol (2012) 0.85
Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification. Int Surg (2013) 0.85
Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors. Ann Surg (2014) 0.84
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist (2016) 0.84
Update on pancreatic neuroendocrine tumors. Gland Surg (2014) 0.83
Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol (2014) 0.83
The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res (2012) 0.82
Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World J Gastroenterol (2015) 0.82
Risk factors for aggressive nonfunctional pancreatic neuroendocrine tumors and the role of endoscopic ultrasound guided fine-needle aspiration. Endosc Ultrasound (2016) 0.81
Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example. World J Clin Cases (2014) 0.81
Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother (2013) 0.81
Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg Today (2012) 0.80
United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World J Gastroenterol (2013) 0.80
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer (2012) 0.80
Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior. Cancer Med (2013) 0.80
Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. Nat Rev Clin Oncol (2016) 0.80
PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma. BMC Cancer (2012) 0.80
Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol (2016) 0.80
Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading. World J Gastroenterol (2015) 0.79
O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer (2015) 0.79
Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with Von Hippel-Lindau syndrome (VHL). Pancreas (2012) 0.79
Somatostatin analogs for gastric carcinoids: For many, but not all. World J Gastroenterol (2015) 0.79
Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. Int J Endocr Oncol (2016) 0.79
Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PLoS One (2016) 0.79
RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner. Cancer Res (2014) 0.78
Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest (2014) 0.78
Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors. Cancer Genet (2015) 0.78
Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging (2012) 0.77
Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience. Dig Dis Sci (2014) 0.77
Comparison of the prognostic values of the 2010 WHO classification, AJCC 7th edition, and ENETS classification of gastric neuroendocrine tumors. Medicine (Baltimore) (2016) 0.77
AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas. Proc Natl Acad Sci U S A (2016) 0.77
Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review. World J Surg (2016) 0.77
Pancreatic insulinomas: Laparoscopic management. World J Gastrointest Endosc (2015) 0.77
Multiple Endocrine Neoplasia: Genetics and Clinical Management. Surg Oncol Clin N Am (2015) 0.77
Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg (2014) 0.76
Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review. ScientificWorldJournal (2012) 0.76
Well-differentiated neuroendocrine tumor of the stomach: A rare case at an uncommon site. Medicine (Baltimore) (2016) 0.75
Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas. World J Gastroenterol (2016) 0.75
Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs). Medicine (Baltimore) (2015) 0.75
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res (2014) 0.75
Pancreatic Neuroendocrine Tumors: an Update. Indian J Surg (2015) 0.75
Neuroendocrine Cancer of Rectum Metastasizing to Ovary. Case Rep Oncol Med (2016) 0.75
Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience (2017) 0.75
Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases. Case Rep Oncol (2016) 0.75
Beyond the whipple operation: radical resections for cancers of the head of the pancreas. Indian J Surg Oncol (2013) 0.75
Weight Gain in Zollinger-Ellison Syndrome After Acid Suppression. Pancreas (2016) 0.75
Non-functioning pancreatic neuroendocrine tumors: Surgery or observation? World J Gastrointest Endosc (2017) 0.75
Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am (2015) 0.75
Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature. Medicine (Baltimore) (2017) 0.75
A Perplexing Case of Abdominal Pain That Led to the Diagnosis of Zollinger-Ellison Syndrome. Case Rep Gastrointest Med (2017) 0.75
Management of the hormonal syndrome of neuroendocrine tumors. Arch Med Sci (2016) 0.75
Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy. Pancreas (2017) 0.75
Well-Differentiated, Non-Functional, Non-Ampullary Duodenal Neuroendocrine Tumors: Toward Defining Evaluation and Management. World J Surg (2016) 0.75
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. J Cancer Res Clin Oncol (2017) 0.75
Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome. Dig Dis Sci (2017) 0.75
Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1. World J Surg (2016) 0.75
Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series. World J Clin Oncol (2017) 0.75
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
A 5-decade analysis of 13,715 carcinoid tumors. Cancer (2003) 12.78
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 9.27
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2006) 5.86
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol (2008) 4.66
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med (1992) 4.33
Current status of gastrointestinal carcinoids. Gastroenterology (2005) 4.26
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med (2007) 3.98
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2007) 3.89
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol (2004) 3.43
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med (1999) 3.21
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer (1991) 2.98
Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg (1996) 2.69
Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol (2005) 2.69
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol (2004) 2.54
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med (1996) 2.51
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology (2005) 2.49
Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol (1997) 2.46
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer (2008) 2.11
Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med (1995) 2.05
Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology (1995) 2.03
Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J (2003) 2.02
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res (2009) 2.00
Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med (1993) 1.94
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94
Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med (1999) 1.92
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) (2000) 1.88
Insulinoma. Best Pract Res Clin Gastroenterol (2005) 1.80
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol (2005) 1.72
Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg (1992) 1.71
Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int (2000) 1.70
Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology (1990) 1.68
Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology (2007) 1.67
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer (2005) 1.67
Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol (2005) 1.65
Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol (2007) 1.64
Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol (2006) 1.64
Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol (1999) 1.59
Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology (1990) 1.56
Gastrinoma (duodenal and pancreatic). Neuroendocrinology (2007) 1.55
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol (2005) 1.49
Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am (2003) 1.48
Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery (2007) 1.48
Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg (2004) 1.45
Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol (2005) 1.45
Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg (2008) 1.45
Pancreatic endocrine tumors. J Surg Res (2004) 1.42
Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab (2005) 1.40
Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2007) 1.40
Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) (2004) 1.39
Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery (1998) 1.38
Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant (2008) 1.38
Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med (2009) 1.36
Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab (2005) 1.35
Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol (2005) 1.35
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol (2007) 1.33
Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) (2006) 1.30
The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol (2004) 1.30
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol (2006) 1.29
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology (2009) 1.28
Diazoxide in the management of patients with insulinoma. World J Surg (1986) 1.27
Surgery increases survival in patients with gastrinoma. Ann Surg (2006) 1.26
Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology (2007) 1.26
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab (2007) 1.25
Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology (1997) 1.23
Laparoscopic approach for solitary insulinoma: a multicentre study. Langenbecks Arch Surg (2004) 1.22
Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med (1998) 1.22
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer (2006) 1.22
Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology (1992) 1.22
Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab (2007) 1.21
Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology (2007) 1.21
Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J (1997) 1.21
Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg (1994) 1.21
Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg (2004) 1.20
Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg (2006) 1.19
Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study. Gastroenterology (1990) 1.18
Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab (2007) 1.17
Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med (1998) 1.15
Location, incidence, and malignant potential of duodenal gastrinomas. Surgery (1991) 1.15
Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg (2001) 1.14
Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) (2001) 1.14
Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol (2009) 1.13
Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab (2007) 1.12
Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab (2005) 1.11
Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the colon and rectum. Arch Pathol Lab Med (2010) 1.10
Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol (2003) 1.10
Cushing's syndrome in patients with the Zollinger-Ellison syndrome. N Engl J Med (1986) 1.09
A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg (1993) 1.08
Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl (2007) 1.06
Well-differentiated gastric tumors/carcinomas. Neuroendocrinology (2007) 1.06
Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep (2004) 1.06
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol (2008) 4.66
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol (2004) 3.43
Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol (2004) 3.08
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol (2005) 3.01
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 2.84
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.71
Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res (2005) 2.67
Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet (2006) 2.62
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas (2010) 2.43
Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol (2005) 2.39
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol (2012) 2.38
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol (2008) 2.27
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol (2004) 2.27
Severe hyponatremia with high urine sodium and osmolality. Clin Chem (2009) 2.22
A pathologic re-review of follicular thyroid neoplasms: the impact of changing the threshold for the diagnosis of the follicular variant of papillary thyroid carcinoma. Surgery (2008) 2.21
Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg (2005) 2.19
Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol (2010) 2.18
Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A (2007) 2.17
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Results after pancreatic resection for metastatic lesions. Ann Surg Oncol (2002) 2.15
Correlation of breast cancer axillary lymph node metastases with stem cell mutations. JAMA Surg (2013) 2.14
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas (2010) 2.13
Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol (2005) 2.12
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med (2002) 2.12
Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol (2003) 2.12
Using complications associated with postmastectomy radiation and immediate breast reconstruction to improve surgical decision making. Arch Surg (2010) 2.11
Clinical role of FDG PET in evaluation of cancer patients. Radiographics (2003) 2.08
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol (2005) 2.07
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab (2009) 2.05
Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J (2003) 2.02
Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res (2011) 2.00
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol (2002) 1.96
Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol (2004) 1.96
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol (2007) 1.95
Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies. J Surg Oncol (2006) 1.95
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology (2012) 1.94
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A (2008) 1.92
Neuroendocrine tumors. J Natl Compr Canc Netw (2012) 1.91
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas (2010) 1.90
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer (2008) 1.88
PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics (2004) 1.88
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst (2011) 1.86
Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol (2007) 1.84
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer (2002) 1.82
Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology (2008) 1.81
The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res (2007) 1.80
Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol (2002) 1.78
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer (2010) 1.76
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol (2011) 1.75
Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res (2010) 1.71
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst (2008) 1.71
Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg (2011) 1.71
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol (2012) 1.71
Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg (2003) 1.70
The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol (2002) 1.68
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol (2005) 1.67
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer (2005) 1.67
Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg (2002) 1.66
Management of primary liver sarcomas. Cancer (2007) 1.65
Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol (2005) 1.65
Lymphoepithelial cysts of the pancreas: a report of 12 cases and a review of the literature. Mod Pathol (2002) 1.65
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery (2003) 1.64
Possible axonal regrowth in late recovery from the minimally conscious state. J Clin Invest (2006) 1.64
Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol (2007) 1.64